PIK3CA and breast carcinoma: INAVO-121 will compare inavolisib plus fulvestrant with alpelisib plus fulvestrant in a population with PIK3CA-mutated, ER+/HER2− advanced, or relapsed breast cancer progressing after ET plus CDK4/6is (NCT05646862).